UAE Rheumatology Drugs Market Analysis Report 2022 to 2030

UAE Rheumatology Drugs Market Analysis

$ 3999

UAE's Rheumatology Drugs Market is projected to grow from $305 Mn in 2022 to $411 Mn by 2030, registering a CAGR of 1.8% during the forecast period of 2022-30. The increasing prevalence of rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, is driving growth in the UAE rheumatology drugs market. These diseases are becoming increasingly prevalent in the UAE due to the aging population and lifestyle-related factors, such as sedentary lifestyles and obesity. Pfizer is one of the leading pharmaceutical companies in the UAE, with a strong presence in the rheumatology drugs market. The company offers a range of rheumatology drugs, including biologic drugs and traditional disease-modifying antirheumatic drugs (DMARDs).

ID: IN10AEPH022 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Shivam Zalke

Buy Now

UAE Rheumatology Drugs Market Executive Summary

UAE's Rheumatology Drugs Market is projected to grow from $305 Mn in 2022 to $411 Mn by 2030, registering a CAGR of 1.8% during the forecast period of 2022-30.

The United Arab Emirates (UAE) rheumatology drugs market is a growing market, driven by the increasing prevalence of rheumatic diseases, the growing demand for biologic drugs, and the increasing healthcare expenditure in the country.

Rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, are becoming increasingly prevalent in the UAE due to the aging population and lifestyle-related factors, such as sedentary lifestyles and obesity.

The UAE rheumatology drugs market is characterized by a high degree of competition, with a large number of multinational and local pharmaceutical companies operating in the market. The market is dominated by biological drugs, which are increasingly being used in the treatment of rheumatic diseases due to their efficacy and high level of specificity.

The healthcare system in the UAE is funded by a combination of public and private funding and is characterized by a high degree of government involvement in the healthcare sector. The government regulates the pricing and reimbursement of drugs and plays a role in the authorization and approval of drugs.

Overall, the UAE rheumatology drugs market is expected to grow in the coming years, driven by the increasing prevalence of rheumatic diseases, the growing demand for biologic drugs, and the increasing healthcare expenditure in the country. Companies operating in the market are expected to continue to invest in R&D in order to develop more effective rheumatology drugs, which will drive market growth.

uae rheumatology drugs market analysis

Market Dynamics

The UAE rheumatology drugs market is driven by several key factors, including:

Increasing prevalence of rheumatic diseases: The increasing prevalence of rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, is driving growth in the UAE rheumatology drugs market. These diseases are becoming increasingly prevalent in the UAE due to the aging population and lifestyle-related factors, such as sedentary lifestyles and obesity.
Growing demand for biologic drugs: Biologic drugs, which are increasingly being used in the treatment of rheumatic diseases due to their efficacy and high level of specificity, are driving growth in the UAE rheumatology drugs market
Increasing healthcare expenditure: The increasing healthcare expenditure in the UAE is driving growth in the rheumatology drugs market, as the government and private sector are investing more in the healthcare sector to improve the quality of healthcare services and increase access to drugs.
Government support: The government in the UAE is actively involved in the healthcare sector and is playing a key role in the regulation and development of the rheumatology drugs market. The government regulates the pricing and reimbursement of drugs and provides support for the development and authorization of new drugs.
R&D investment: Companies operating in the UAE rheumatology drugs market are investing in R&D to develop more effective rheumatology drugs, which will drive market growth. This investment is driven by the increasing demand for rheumatology drugs, the growing prevalence of rheumatic diseases, and the growing healthcare expenditure in the UAE.

These key drivers are expected to continue to drive growth in the UAE rheumatology drugs market in the coming years, as the demand for effective rheumatology drugs continues to increase and the government and private sector continue to invest in the healthcare sector.

Competitive Landscape

Key Players

There are several key players operating in the UAE rheumatology drugs market, including:

Pfizer Inc.: Pfizer is one of the leading pharmaceutical companies in the UAE, with a strong presence in the rheumatology drugs market. The company offers a range of rheumatology drugs, including biologic drugs and traditional disease-modifying antirheumatic drugs (DMARDs).
Roche: Roche is a Swiss multinational pharmaceutical company that is active in the UAE rheumatology drugs market. The company offers a range of biological drugs for the treatment of rheumatic diseases.
AbbVie: AbbVie is a global pharmaceutical company that is active in the UAE rheumatology drugs market. The company offers a range of biologic drugs for the treatment of rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Novartis: Novartis is a Swiss multinational pharmaceutical company that is active in the UAE rheumatology drugs market. The company offers a range of biological drugs for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis.
Sanofi: Sanofi is a French multinational pharmaceutical company that is active in the UAE rheumatology drugs market. The company offers a range of biological drugs for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis.

These are some of the key players operating in the UAE rheumatology drugs market, and the market is characterized by a high degree of competition, with a large number of multinational and local pharmaceutical companies operating in the market. Companies are expected to continue to invest in R&D in order to develop more effective rheumatology drugs, which will drive market growth in the coming years.

Healthcare Policies and Regulatory Landscape

The healthcare policies and regulatory landscape for rheumatology drugs in the United Arab Emirates (UAE) are governed by the Ministry of Health and Prevention (MOHAP). The MOHAP is responsible for regulating and supervising the healthcare sector in the country, including the import, distribution, and sale of pharmaceutical products.

In terms of rheumatology drugs, the MOHAP has established strict regulations for the approval, pricing, and marketing of these products. The approval process for new rheumatology drugs involves a thorough review and assessment of safety, efficacy, and quality data by the MOHAP's Drug Registration and Evaluation Department.

In addition to this, the MOHAP also regulates the pricing of rheumatology drugs through its Pharmaceutical Pricing Committee. This committee is responsible for setting the maximum retail price for pharmaceutical products in the UAE, based on factors such as the cost of production, import, and distribution.

Overall, the regulatory landscape in the UAE is designed to ensure the safety and quality of rheumatology drugs available to patients, while also promoting affordability and accessibility. The MOHAP continues to monitor and update its policies and regulations in order to ensure the highest standards in the healthcare sector.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Rheumatology Drug Market Segmentation

Drug Class

The disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost the growth of the segment.

Disease-modifying anti-rheumatic drugs (DMARDs)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Uric acids
Others

Route of administration

Oral
Parental

Sales channel

Depending on the sales channel, the prescription-based drug segment is the major shareholder in the UAE rheumatoid drugs market, owing to the advantages offered by prescription-based drugs.

Prescription-based drugs
OTC

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.